Skip to main content

Advertisement

SpringerLink
Log in

Expanded algorithm for managing patients with acute decompensated heart failure

  • Published:
Heart Failure Reviews Aims and scope Submit manuscript

Abstract

Heart failure is a complex disease process, the manifestation of various cardiac and noncardiac abnormalities. General treatment approaches for heart failure have remained the same over the past decades despite the advent of novel therapies and monitoring modalities. In the same vein, the readmission rates for heart failure patients remain high and portend a poor prognosis for morbidity and mortality. In this context, development and implementation of improved algorithms for assessing and treating HF patients during hospitalization remains an unmet need. We propose an expanded algorithm for both monitoring and treating patients admitted for acute decompensated heart failure with the goal to improve post-discharge outcomes and decrease rates of rehospitalizations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Gheorghiade M, Vaduganathan M, Fonarow GC, Bonow RO (2013) Rehospitalization for heart failure. Probl Perspect JACC 61(4):391–403

    Google Scholar 

  2. O’Connor CM, Miller AB, Blair JE et al (2010) Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome study with Tolvaptan (EVEREST) program. Am Heart J 159:841–849

    Article  PubMed  CAS  Google Scholar 

  3. Solomon SD, Dobson J, Pocock S, Skali H, McMurray JJV, Granger CB, Yusuf S, Swedberg K, Young JB, Michelson EL, Pfeffer MA, for the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) Investigators (2007) Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation 116(13):1482–1487

    Article  PubMed  Google Scholar 

  4. Ramirez A, Abelmann WH (1974) Cardiac decompensation. NEJM 290(9):499–501

    Article  PubMed  CAS  Google Scholar 

  5. Peacock WF, Braunwald E, Abraham W, Albert N, Burnett J, Christenson R, Collins S, Diercks D, Fonarow G, Hollander J, Kellerman A, Gheorghiade M, Kirk D, Levy P, Maisel A, Massie BM, O'Connor C, Pang P, Shah M, Sopko G, Stevenson L, Storrow A, Teerlink J (2010) National Heart, Lung and Blood Institute working group on emergency department management of acute heart failure: research challenges and opportunities. JACC. 56(5):343–351

    Article  PubMed  Google Scholar 

  6. Hamo CE, Butler J, Gheorghiade M, Chioncel O (2016) The bumpy road to drug development for acute heart failure. Eur Heart J Supp 18(Supplement G):G19–G32

    Article  CAS  Google Scholar 

  7. Gheorghiade M, Braunwald E (2011) A proposed model for initial assessment and management of acute heart failure syndromes. JAMA 305:1702–1703

    Article  PubMed  CAS  Google Scholar 

  8. Ponikowski P, Voors AA, Anker SD et al (2016) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association of the ESC. Eur Heart J 37(27):2129–2200

    Article  PubMed  Google Scholar 

  9. Cleland JG, Pennel D, Ray S, Murray G, MacFarlane P, Cowley A, Coats A, Lahiri A (1999) The Carvedilol Hibernation Reversible Ischemia Trial: Marker of Success (CHRISTMAS). Eur J Heart Fail 1:191–196

    Article  PubMed  CAS  Google Scholar 

  10. Cleland JG, Pennell DJ, Ray SG, Coats AJ, Macfarlane PW, Murray GD, Mule JD, Vered Z, Lahiri A, Carvedilol hibernating reversible ischaemia trial: marker of success investigators, On behalf of the CHRISTMAS (Carvedilol Hibernating Reversible Ischaemia Trial: Maker of Success) investigators (2003) Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial. Lancet 362:14–21

    Article  PubMed  CAS  Google Scholar 

  11. Greene SJ, Vaduganathan M, Gheorghiade M (2017) Finding the road to recovery: therapeutic and clinical trial implications of dysfunctional viable myocardium in heart failure with reduced ejection fraction. Eur J Heart Fail 19(7):870–872

    Article  PubMed  Google Scholar 

  12. Adamsom PB, Magalski A, Braunschweig F et al (2003) Ongoing right ventricular hemodynamics in heart failure: clinical value of measurements derived form an implantable monitoring system. J Am Coll Cardiol 41:565–571

    Article  Google Scholar 

  13. Zile MR, Bennett TD, St John Sutton M et al (2008) Transition from chronic compensated to acute decompensated heart failure: pathophysiological insights obtained from continuous monitoring of intracardiac pressures. Circulation 118(14):1433–1441

    Article  PubMed  Google Scholar 

  14. Stevenson LW, Perloff JK (1989) The limited reliability of physical signs for estimating hemodynamics in chronic heart failure. JAMA 261:884–888

    Article  PubMed  CAS  Google Scholar 

  15. Gheorghiade M, Follath F, Ponikowski P, Barsuk JH, Blair JE, Cleland JG, Dickstein K, Drazner MH, Fonarow GC, Jaarsma T, Jondeau G, Sendon JL, Mebazaa A, Metra M, Nieminen M, Pang PS, Seferovic P, Stevenson LW, van Veldhuisen D, Zannad F, Anker SD, Rhodes A, McMurray J, Filippatos G, European Society of Cardiology, European Society of Intensive Care Medicine (2010) Assessing and grading congestion in acute heart failure. Eur J Heart Fail 12(5):423–433

    Article  PubMed  Google Scholar 

  16. Ambrosy AP, Khan H, Udelson JE, Mentz RJ, Chioncel O, Greene SJ, Vaduganathan M, Subacuis HP, Konstam MA, Swedberg K, Zannad F, Maggioni AP, Gheorghiade M, Butler J (2016) Changes in dyspnea status during hospitalization and post-discharge health-related quality of life in hospitalized patients with heart failure: findings from the EVEREST trial. Circ Heart Fail. 9:e002458

    Article  PubMed  Google Scholar 

  17. Pang PS, Collins SP, Sauser K, Andrei AC, Storrow AB, Hollander JE, Tavares M, Spinar J, Macarie C, Raev D, Nowak R, Gheorghiade M, Mebazaa A (2014) Assessment of dyspnea early in acute heart failure: patient characteristics and response differences between Likert and visual analog scales. Acad Emerg Med 21(6):659–666

    Article  PubMed  PubMed Central  Google Scholar 

  18. AbouEzzeddine OF, Lala A, Khazanie PP et al (2016) Evaluation of a provocative dyspnea severity score in acute heart failure. Am Heart J 172:34–41

    Article  PubMed  Google Scholar 

  19. McGee S, Abernethy WB, Simel DL (1999) The rational clinical examination. Is this patient hypovolemic? JAMA 281:1022–1029

    Article  PubMed  CAS  Google Scholar 

  20. Gheorghiade M, Follath F, Ponikowski P, Barsuk JH, Blair JE, Cleland JG, Dickstein K, Drazner MH, Fonarow GC, Jaarsma T, Jondeau G, Sendon JL, Mebazaa A, Metra M, Nieminen M, Pang PS, Seferovic P, Stevenson LW, van Veldhuisen D, Zannad F, Anker SD, Rhodes A, McMurray J, Filippatos G, European Society of Cardiology, European Society of Intensive Care Medicine (2010) Assessing and grading congestion in acute heart failure: a scientific statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. Eur J Heart Fail 12:423–433

    Article  PubMed  Google Scholar 

  21. Felker GM, Cuculich PS, Gheorghiade M (2006) The Valsalva maneuver: a bedside ‘biomarker’ for heart failure. Am J Med 119:117–122

    Article  PubMed  Google Scholar 

  22. Knowles JH, Gorlin R, Storey CF (1956) Clinical test for pulmonary congestion with use of the Valsalva maneuver. JAMA 160:44–48

    Article  CAS  Google Scholar 

  23. Weilenmann D, Rickli H, Follath F, Kiowski W, Brunner-la Rocca HP (2002) Noninvasive evaluation of pulmonary capillary wedge pressure by BP response to the Valsalva maneuver. Chest 122:140–145

    Article  PubMed  Google Scholar 

  24. Binanay C, Califf RM, Hasselblad V, O'Connor CM, Shah MR, Sopko G, Stevenson LW, Francis GS, Leier CV, Miller LW, ESCAPE Investigators and ESCAPE Study Coordinators (2005) Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. JAMA 294:1625–1633

    Article  PubMed  Google Scholar 

  25. Chioncel O, Collins SP, Greene SJ, Ambrosy AP, Vaduganathan M, Macarie C, Butler J, Gheorghiade M (2016) Natriuretic peptide-guided management in heart failure. J Cardiovasc Med 17(8):556–568

    Article  CAS  Google Scholar 

  26. Seino Y, Ogawa A, Yamashita T, Fukushima M, Ogata KI, Fukumoto H, Takano T (2004) Application of NT-proBNP and BNP measurements in cardiac care: a more discerning marker for the detection and evaluation of heart failure. Eur J Heart Fail 6(3):295–300

    Article  PubMed  CAS  Google Scholar 

  27. Fonarow GC, Peacock WF, Phillips CO, Givertz MM, Lopatin M, ADHERE Scientific Advisory Committee and Investigators (2007) Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure. JACC. 49:1943–1950

    Article  PubMed  CAS  Google Scholar 

  28. Cohen-Solal A, Logeart D, Huang B, Cai D, Nieminen MS, Mebazaa A (2009) Lowered B-type natriuretic peptide in response to levosimendan or dobutamine treatment is associated with improved survival in patients with severe acutely decompensated heart failure. JACC 53(25):2343–2348

    Article  PubMed  CAS  Google Scholar 

  29. Ferre RM, Chioncel O, Pang PS, Lang RM, Gheorghiade M, Collins SP (2015) Acute heart failure: the role of focused emergency cardiopulmonary ultrasound in identification and early management. Eur J Heart Fail 17:1223–1227

    Article  PubMed  Google Scholar 

  30. Goonewardena SN, Gemignani A, Ronan A, Vasaiwala S, Blair J, Brennan JM, Shah DP, Spencer KT (2008) Comparison of hand-carried ultrasound assessment of the inferior vena cava and N-terminal pro-brain natriuretic peptide for predicting readmission after hospitalization for acute decompensated heart failure. JACC Cardiovasc Imaging 1(5):595–601

    Article  PubMed  Google Scholar 

  31. Van De Water JM, Miller TW (2003) Impedance cardiography: the next vital sign technology? Chest 123(6):2028–2033

    Article  Google Scholar 

  32. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJV, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Wilson Tang WH, Tsai EJ, Bruce L (2013) Wilkoff. 2013 ACCF/AHA guideline for the management of heart failure. Circulation 128:e240–e327

    Article  PubMed  Google Scholar 

  33. Testani JM, Chen J, McCauley BD et al (2010) Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival. Circulation 122:265–272

    Article  PubMed  PubMed Central  Google Scholar 

  34. Greene SJ, Gheorghiade M, Vaduganathan M, Ambrosy AP, Mentz RJ, Subacius H, Maggioni AP, Nodari S, Konstam MA, Butler J, Filippatos G, on behalf of the EVEREST Trial investigators (2013) EVEREST trial investigators: Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. Eur J Heart Fail 15:1401–1411

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  35. Testani JM, Kimmel SE, Dries DL, Coca SG (2011) Prognostic importance of early worsening renal function after initiation of angiotensin-converting enzyme inhibitor therapy in patients with cardiac dysfunction. Circ Heart Fail 4(6):685–691

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  36. Rossignol P, Cleland JG, Bhandari S et al (2012) Determinants and consequences of renal function variations with aldosterone blocker therapy in heart failure patients after myocardial infarction: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study. Circulation 125:271–279

    Article  PubMed  CAS  Google Scholar 

  37. Golwala HB et al (2013) Use of hydralazineisosorbide dinitrate combination in African American and other race/ethnic group patients with heart failure and reduced left ventricular ejection fraction. J Am Heart Assoc 2:e000214

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  38. Gheorghiade M, Braunwald E (2009) Reconsidering the role for digoxin in the management of acute heart failure syndromes. JAMA 302:2146–2147

    Article  PubMed  Google Scholar 

  39. The Digitalis Investigation Group (1997) The effect of digoxin on mortality and morbidity in patients with heart failure. NEJM 336:525–533

    Article  Google Scholar 

  40. Albert NM, Yancy CW, Liang L, Zhao X, Hernandez AF, Peterson ED, Cannon CP, Fonarow GC (2009) Use of aldosterone antagonists in heart failure. JAMA 302:1658–1665

    Article  PubMed  CAS  Google Scholar 

  41. Schrier RW, Gheorghiade M (2011) Challenge of rehospitalizations for heart failure: potential of natriuretic doses of mineralocorticoid receptor antagonists. Am Heart J 161:221–223

    Article  PubMed  Google Scholar 

  42. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. NEJM 341:709–717

    Article  PubMed  CAS  Google Scholar 

  43. Gines P, Schrier RW (2009) Renal failure in cirrhosis. NEJM 361:1279–1290

    Article  PubMed  CAS  Google Scholar 

  44. Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Harty B, Heitner JF, Kenwood CT, Lewis EF, O'Meara E, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, Yang S, McKinlay S, TOPCAT Investigators (2014) Spironolactone for heart failure with preserved ejection fraction. NEJM 370(15):1383–1392

    Article  PubMed  CAS  Google Scholar 

  45. Bikdeli B, Strait KM, Dharmarajan K, Partovian C, Coca SG, Kim N, Li SX, Testani JM, Khan U, Krumholz HM (2013) Dominance of furosemide for loop diuretic therapy in heart failuretime to revisit the alternatives? JACC 61(14):1549–1550

    Article  PubMed  PubMed Central  Google Scholar 

  46. Müller K, Gamba G, Jaquet F, Hess B (2003) Torasemide vs. furosemide in primary care patients with chronic heart failure NYHA II to IV—efficacy and quality of life. Eur J Heart Fail 5(6):793–801

    Article  PubMed  CAS  Google Scholar 

  47. Kasama S, Toyama T, Hatori T, Sumino H, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, Kurabayashi M (2006) Effects of torasemide on cardiac sympathetic nerve activity and left ventricular remodelling in patients with congestive heart failure. Heart 92(10):1434–1440

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  48. Vargo DL, Kramer WG, Black PK, Smith WB, Serpas T, Brater DC (1995) Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure. Clin Pharmacol Ther 57(6):601–609

    Article  PubMed  CAS  Google Scholar 

  49. Buggey J, Mentz RJ, Pitt B, Eisenstein EL, Anstrom KJ, Velazquez EJ, O'Connor CM (2015) A reappraisal of loop diuretic choice in heart failure patients. Am Heart J 169(3):323–333

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  50. Bleske BE, Welage LS, Kramer WG, Nicklas JM (1998) Pharmacokinetics of torsemide in patients with decompensated and compensated congestive heart failure. J Clin Pharmacol 38(8):708–714

    Article  PubMed  CAS  Google Scholar 

  51. Elhassan EA, Schrier RW. Disorders of extracellular volume. Compr Clin Nephrol (4e). 2010. 80–93. Print

  52. Ellison DH (1991) The physiologic basis of diuretic synergism: its role in treating diuretic resistance. Ann Int Med 114(10):886–894

    Article  PubMed  CAS  Google Scholar 

  53. Swedberg K, Komajda M, Bohm M et al (2010) Ivabradine and outcomes in chronic heart failure (SHIFT): a randomized placebo-controlled study. Lancet 376(9744):875–885

    Article  PubMed  CAS  Google Scholar 

  54. Segura LM (2011) Dual-acting angiotensin receptor-neprilysin inhibition. Curr Hypertens Rep 13:74–78

    Article  PubMed  CAS  Google Scholar 

  55. McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, PARADIGM-HF Investigators and Committees (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371:993–1004

    Article  PubMed  CAS  Google Scholar 

  56. Xie W, Zheng F, Song X, Zhong B, Yan L (2016) Renin-angiotensin-aldosterone system blockers for heart failure with reduced ejection fraction or left ventricular dysfunction: network meta-analysis. Int J Cardiol 205:65–71

    Article  PubMed  Google Scholar 

  57. Desai AS, Claggett BL, Packer M, Zile MR, Rouleau JL, Swedberg K, Shi V, Lefkowitz M, Starling R, Teerlink J, McMurray J, Solomon SD, PARADIGM-HF Investigators (2016) Influence of sacubitril/valsartan (LCZ696) on 30-day readmission after heart failure hospitalization. J Am Coll Cardiol 68(3):241–248

    Article  PubMed  CAS  Google Scholar 

  58. Li PK, Chow KM, tal V d LMW e (2017) Changes in the worldwide epidemiology of peritoneal dialysis. Nat Rev Nephrol 13(2):90–103

    Article  PubMed  CAS  Google Scholar 

  59. Bart BA, Goldsmith SR, Lee KL et al (2012) Ultrafiltration in decompensated heart failure with cardiorenal syndrome. NEJM 367:2296–2304

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  60. Costanzo MR, Negoianu D, Jaski BE, Bart BA, Heywood JT, Anand IS, Smelser JM, Kaneshige AM, Chomsky DB, Adler ED, Haas GJ, Watts JA, Nabut JL, Schollmeyer MP, Fonarow GC (2016) Aquapheresis versus intravenous diuretics and hospitalizations for heart failure. JACC: Heart Failure 4(2):95–105

    PubMed  Google Scholar 

  61. Mehrotra R, Kathuria P Place of peritoneal dialysis in the management of treatment-resistant congestive heart failure. Kidney Int Suppl 103:S67–S71

  62. Cnossen TT, Kooman JP, Konings CJ (2010) Peritoneal dialysis in patients with primary cardiac failure complicated by renal failure. Blood Purif 20:146–152

    Article  Google Scholar 

  63. Nunez J, Gonazalez M, Minana G et al (2012) Continuous ambulatory peritoneal dialysis as a therapeutic alternative in patients with advanced congestive heart failure. Eur J Heart Fail 14:540–548

    Article  PubMed  CAS  Google Scholar 

  64. Chioncel O, Lainscak M, Seferovic PM, Anker SD, Crespo-Leiro MG, Harjola VP, Parissis J, Laroche C, Piepoli MF, Fonseca C, Mebazaa A, Lund L, Ambrosio GA, Coats AJ, Ferrari R, Ruschitzka F, Maggioni AP, Filippatos G (2017) Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 19:1574–1585. https://doi.org/10.1002/ejhf.813

    Article  PubMed  CAS  Google Scholar 

  65. Adams JKF, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, Abraham WT, Berkowitz RL, Galvao M, Horton DP (2005) Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 149:209–216

    Article  PubMed  Google Scholar 

  66. Ments RJ, Kelly JP, von Lueder TG et al (2014) Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction. JACC. 64(21):2281–2293

    Article  Google Scholar 

  67. Bahrami H, Bluemke DA, Kronmal R, Bertoni AG, Lloyd-Jones DM, Shahar E, Szklo M, Lima JAC (2008) Novel metabolic risk factors for incident heart failure and their relationship with obesity: the MESA (Multi-Ethnic Study of Atherosclerosis) study. JACC. 51:1775–1783

    Article  PubMed  CAS  Google Scholar 

  68. Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJV (2009) Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicenter, randomized, open-label trial. Lancet 373(9681):2125–2135

    Article  PubMed  CAS  Google Scholar 

  69. Scirica BM, Bhatt D, Braunwald E et al (2013) Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus (SAVOR-TIMI 53). NEJM 369:1317–1326

    Article  PubMed  CAS  Google Scholar 

  70. Grempler R, Thomas L, Eckhardt M, Himmelsbach F, Sauer A, Sharp DE, Bakker RA, Mark M, Klein T, Eickelmann P (2012) Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterization and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab 14:83–90

    Article  PubMed  CAS  Google Scholar 

  71. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE, EMPA-REG OUTCOME Investigators (2015) Empagliflozin, cardiovascular outcomes and mortality in type 2 diabetes. NEJM 373(22):2117–2128

    Article  PubMed  CAS  Google Scholar 

  72. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR, CANVAS Program Collaborative Group (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. NEJM 377:644–657

    Article  PubMed  CAS  Google Scholar 

  73. Groenveld HF, Januzzi JL, Damman K, van Wijngaarden J, Hillege HL, van Veldhuisen DJ, van der Meer P (2008) Anemia and mortality in heart failure patients: a systematic review and meta-analysis. JACC. 52:818–827

    Article  PubMed  Google Scholar 

  74. Tang YD, Katz SD (2006) Anemia in chronic heart failure: prevalence, etiology, clinical correlates, and treatment options. Circ. 113:2454–2461

    Article  Google Scholar 

  75. Jankowska EA, Rozentryt P, Witkowska A, Nowak J, Hartmann O, Ponikowska B, Borodulin-Nadzieja L, Banasiak W, Polonski L, Filippatos G, McMurray JJV, Anker SD, Ponikowski P (2010) Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J 31:1872–1880

    Article  PubMed  CAS  Google Scholar 

  76. Swedberg K, Young JB, Anand IS, Cheng S, Desai AS, Diaz R, Maggioni AP, McMurray J, O'Connor C, Pfeffer MA, Solomon SD, Sun Y, Tendera M, van Veldhuisen D, RED-HF Committees, RED-HF Investigators (2013) Treatment of anemia with darbepoietin alfa in systolic heart failure. NEJM 368:1210–1219

    Article  PubMed  CAS  Google Scholar 

  77. Lewis GD, Malhotra R, Hernandez AF, McNulty SE, Smith A, Felker GM, Tang WHW, LaRue SJ, Redfield MM, Semigran MJ, Givertz MM, van Buren P, Whellan D, Anstrom KJ, Shah MR, Desvigne-Nickens P, Butler J, Braunwald E, for the NHLBI Heart Failure Clinical Research Network (2017) Effects of oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency. JAMA 317(19):1958–1966

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  78. Gerasimos F, Dimitrios F, Comin C et al (2013) Intravenous ferric carboxymaltose in iron-defcient chronic heart failure patients with and without anaemia: a subanalysis of the FAIR-HF trial. Eur J Heart Fail 15:1267–1276

    Article  CAS  Google Scholar 

  79. Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, McDonagh T, Parkhomenko A, Tavazzi L, Levesque V, Mori C, Roubert B, Filippatos G, Ruschitzka F, Anker SD, for the CONFIRM-HF Investigators (2015) Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J 36(11):657–668

    Article  PubMed  CAS  Google Scholar 

  80. van Velhuisen DJ, Ponikowski PI, van der Meer P et al (2017) Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. Circulation; CIRCULATIONAHA 117:02749

    Google Scholar 

  81. Greene SJ, Fonarow GC, Vaduganathan M, Khan SS, Butler J, Gheorghiade M (2015) The vulnerable phase after hospitalization for heart failure. Nat Rev Cardiol 12(4):220–229

    Article  PubMed  Google Scholar 

  82. Hernandez AF, Greiner MA, Fonarow GC, Hammill BG, Heidenreich PA, Yancy CW, Peterson ED, Curtis LH (2010) Relationship between early physician follow-up and 30-day readmission among Medicare beneficiaries hospitalized for heart failure. JAMA 303:1716–1722

    Article  PubMed  CAS  Google Scholar 

  83. Harinstein ME, Flaherty JD, Fonarow GC, Mehra MR, Lang RM, Kim RJ, Cleland JG, Knight BP, Pang PS, Bonow RO, Gheorghiade M (2011) Clinical assessment of acute heart failure syndromes: emergency department through the early post-discharge period. Heart 97:1607–1618

    Article  PubMed  Google Scholar 

  84. Green CP, Porter CB, Bresnahan DR, Spertus JA (2000) Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. JACC. 35(5):1245–1255

    Article  PubMed  CAS  Google Scholar 

  85. Dai S et al (2016) Kansas City Cardiomyopathy Questionnaire Utility in prediction of 30 day readmission rate in patients with chronic heart failure. Cardiol Res Pract 2016(2016):4571201

    PubMed  PubMed Central  Google Scholar 

  86. Greene SJ, Maggioni AP, Fonarow GC et al (2015) Clinical profile and prognostic significance of natriuretic peptide trajectory following hospitalization for worsening chronic heart failure: findings from the ASTRONAUT trial. Eur J Heart Fail 17(1):98–108

    Article  PubMed  CAS  Google Scholar 

  87. Greene SJ, Butler J, Fonarow GC et al (2017) Pre-discharge and early post-discharge troponin elevation among patients hospitalized for heart failure with reduced ejection fraction: findings from the ASTRONAUT trial. Eur J Heart Fail 20:281–291. https://doi.org/10.1002/ejhf.1019

    Article  PubMed  CAS  Google Scholar 

  88. Metra M, Gheorghiade M, Bonow RO, Dei Cas L (2010) Postdischarge assessment after a heart failure hospitalization: the next step forward. Circ 122:1782–1785

    Article  Google Scholar 

  89. Flynn KE, Pina IL, Whellan DJ et al (2009) Effects of exercise training on health status in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA 301(14):1451–1459

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  90. Golwala H, Pandey A, Ju C, Butler J, Yancy C, Bhatt DL, Hernandez AF, Fonarow GC (2015) Temporal trends and factors associated with cardiac rehabilitation referral among patients hospitalized with heart failure findings from Get with the Guidelines—Heart Failure Registry. JACC. 66(8):917–926

    Article  PubMed  Google Scholar 

  91. Varnfield M, Karunanithi M, Lee CK, Honeyman E, Arnold D, Ding H, Smith C, Walters DL (2014) Smartphone-based home care model improved use of cardiac rehabilitation in postmyocardial infarction patients: results from a randomized controlled trial. Heart 100:1770–1779

    Article  PubMed  Google Scholar 

  92. Abraham W et al (2011) Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomized controlled trial. Lancet 377:658–666

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA

    Joyce N. Njoroge, Baljash Cheema & Mihai Gheorghiade

  2. Duke Clinical Research Institute and Division of Cardiology, Duke University Medical Center, Durham, NC, USA

    Andrew P. Ambrosy & Stephen J. Greene

  3. Vanderbilt University Medical Center, Nashville, TN, USA

    Sean P. Collins

  4. Brigham and Women’s Hospital Heart and Vascular Center and Harvard Medical School, Boston, MA, USA

    Muthiah Vaduganathan

  5. Department of Anesthesia and Critical Care, Inserm U942, Hôpitaux Universitaires Saint-Louis-Lariboisière, Paris, France

    Alexandre Mebazaa

  6. University Paris Diderot, Paris, France

    Alexandre Mebazaa

  7. Institute of Emergency for Cardiovascular Diseases “Prof C.C.Iliescu”, Bucharest, Romania

    Ovidiu Chioncel

  8. University of Medicine and Pharmacy Carol Davila, Bucharest, Romania

    Ovidiu Chioncel

  9. Department of Medicine, University of Mississippi, Oxford, MS, USA

    Javed Butler

Authors
  1. Joyce N. Njoroge
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Baljash Cheema
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Andrew P. Ambrosy
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Stephen J. Greene
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sean P. Collins
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Muthiah Vaduganathan
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Alexandre Mebazaa
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ovidiu Chioncel
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Javed Butler
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Mihai Gheorghiade
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joyce N. Njoroge.

Ethics declarations

Conflict of interest

Dr. Muthiah Vaduganathan is supported by the NHLBI T32 postdoctoral training grant (T32HL007604); Dr. Andrew P. Ambrosy is supported by the NHLBI T32 postdoctoral training grant (5T32HL069749); Dr. Sean P. Collins is supported by grants through the AHA, PCORI, NIH, AHRQ, and Novartis and is a consultant for Novartis.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Njoroge, J.N., Cheema, B., Ambrosy, A.P. et al. Expanded algorithm for managing patients with acute decompensated heart failure. Heart Fail Rev 23, 597–607 (2018). https://doi.org/10.1007/s10741-018-9697-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10741-018-9697-9

Keywords

Search

Navigation